MorphoSys Initiates Program Against Drug-Resistant MRSA Infections
MorphoSys Secures Access to Innovative Targets through In-licensing and Collaboration Agreement with Absynth Biologics
MorphoSys AG announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics, providing access to novel target molecules associated with Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus). MorphoSys will generate antibodies using its proprietary HuCAL PLATINUM antibody library which Absynth will test in relevant disease models. MorphoSys will be solely responsible for the development and partnering of the resulting compounds. Absynth will receive an upfront payment and is eligible for development-dependent milestone payments and royalties. Further financial details were not disclosed.
"This collaboration brings together Absynth's novel, proprietary targets and expertise in S. aureus including MRSA and MorphoSys's expertise in the generation of antibody drugs. We see these new targets as a very promising basis of antibody therapy for an increasingly serious medical problem," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Our goal is to create a valuable package of proprietary targets together with high-affinity antibodies, supported by compelling data, which will allow us to partner the program for subsequent development. The targets identified by Absynth represent a unique opportunity to generate value rather quickly and create out-licensing opportunities much earlier than in the areas of cancer and inflammation, which remain however the main focus areas for our discovery and development organization."
"We are delighted to be collaborating with MorphoSys," commented Dr Fiona Marston, Chief Executive, Absynth Biologics Limited. "The synergies between our technologies enhance the prospects of creating products to benefit patients suffering from S. aureus infections."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
